Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Neumora Therapeutics, Inc. | 7,395,185 | reported | 17 Feb 2026 | tx 23+9,754,576−6,013,807 |
| Lyell Immunopharma, Inc. | 1,426,528 | reported | 06 Mar 2026 | tx 1+488,090 |
| Cellectar Biosciences, Inc. | 117,371 | reported | 20 Apr 2016 | tx 4+244,742 |
| VYNE Therapeutics Inc. | 65,780 | reported | 25 Jun 2019 | tx 2+45,000 |
| Unity Biotechnology, Inc. | 10,000 | reported | 21 Jun 2024 | tx 8+119,261−3,261 |
| Jazz Pharmaceuticals plc | 8,290 | reported | 05 Aug 2021 | tx 54+217,433−171,293 |
| Metsera, Inc. | 0 | reported | 13 Nov 2025 | tx 12+8,341,899−34,725,141 |
| BONE CARE INTERNATIONAL INC | 0 | reported | 22 Jun 2004 | tx 4+130,000 |
| CM Life Sciences III Inc. | 0 | reported | 09 Nov 2023 | tx 7+814,354−814,354 |
| Anacor Pharmaceuticals Inc | 0 | reported | 24 Jun 2016 | tx 55+1,084,206−1,088,206 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 06 Mar 2026 | PURCHASE | Lyell Immunopharma, Inc. | 488,090 | 25.61 USD | first after silence |
| 17 Feb 2026 | SALE | Neumora Therapeutics, Inc. | 9,819 | 3.51 USD | |
| 08 Jan 2026 | GRANT_AWARD | Neumora Therapeutics, Inc. | 1,650,000 | 0.00 USD | deriv |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 957,559 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 7,523,682 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 4,031 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 8,313,680 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 223,430 | — | deriv |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 24,188 | — | deriv |
| 13 Nov 2025 | GRANT_AWARD | Metsera, Inc. | 4,031 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 955,864 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 342,500 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 2,000,000 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 497,049 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 955,864 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 342,500 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 497,049 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 2,000,000 | — | deriv |
| 20 May 2025 | GRANT_AWARD | Metsera, Inc. | 24,188 | 0.00 USD | deriv |
| 18 Feb 2025 | SALE | Neumora Therapeutics, Inc. | 13,871 | 1.69 USD | |
| 13 Feb 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 955,864 | — | deriv |
| 13 Feb 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 497,049 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 342,500 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 955,864 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 497,049 | — | deriv |
4 purchases reported after at least 12 months of silence — most recent on 06 Mar 2026.